- |||||||||| Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
[VIRTUAL] 4-YEAR OUTCOMES OF B/F/TAF IN TREATMENT-NAIVE ADULTS () - Mar 18, 2021 - Abstract #CROI2021CROI_624;
Similar outcomes were demonstrated in participants who switched from DTG-containing regimens to B/F/TAF. These results confirm long term safety and efficacy of B/F/TAF.
- |||||||||| Symtuza (darunavir/cobicistat/emtricitabine/tenofovir alafenamide) / J&J, Gilead, Triumeq (dolutegravir/abacavir/lamivudine) / ViiV Healthcare, Descovy (emtricitabine/tenofovir alafenamide) / Gilead
[VIRTUAL] D/C/F/TAF VS DTG/ABC/3TC FOR INITIAL TREATMENT IN HIV+ ADULTS: A RANDOMIZED STUDY () - Mar 18, 2021 - Abstract #CROI2021CROI_622;
P4
D/C/F/TAF administered as a STR did not reach statistical noninferiority vs. DTG/ABC/3TC in the ITTe analysis, nor in ITT sensitivity analyses. Both regimens were well tolerated with a similar increase in CD4 counts, weight or BMI.
- |||||||||| Triumeq (dolutegravir/abacavir/lamivudine) / ViiV Healthcare, Descovy (emtricitabine/tenofovir alafenamide) / Gilead
[VIRTUAL] REVERSIBILITY OF SLEEP DISTURBANCES AFTER SWITCHING FROM DTG/3TC/ABC TO DRV/C/FTC/TAF () - Mar 18, 2021 - Abstract #CROI2021CROI_533;
Sleep disturbances detected through self-reported screening tools seem to be associated with patients on DTG/3TC/ABC not complaining of insomnia. These disturbances, among other neuropsychiatric symptoms such as anxiety or depression, could improve after switching to DRV/c/FTC/TAF.
- |||||||||| Triumeq (dolutegravir/abacavir/lamivudine) / ViiV Healthcare
[VIRTUAL] A Case of Immune Reconstitution Inflammatory Syndrome with Pneumonia () - Mar 14, 2021 - Abstract #ATS2021ATS_4595;
The recovery of immunological function resulted in the unmasking of unrecognized preexisting left lower lobe pneumonia in our patient, which is a classical feature of IRIS. The early recognition of the possibility of IRIS with underlying pneumonia resulted in the initiation of appropriate medical management and prompt recovery.
- |||||||||| Triumeq (dolutegravir/abacavir/lamivudine) / ViiV Healthcare, Tivicay (dolutegravir) / ViiV Healthcare
Clinical, Journal: INCREASED EXPOSURE TO ANTIRETROVIRALS FOLLOWING SLEEVE GASTRECTOMY - A CASE REPORT. (Pubmed Central) - Feb 23, 2021
Significantly increased levels were measured, particularly for abacavir, whose levels increased approximately 12-fold. Several mechanistic explanations for these findings are discussed.
- |||||||||| Triumeq (dolutegravir/abacavir/lamivudine) / ViiV Healthcare
Journal: Triumeq Increases Excitability of Pyramidal Neurons in the Medial Prefrontal Cortex by Facilitating Voltage-Gated Ca Channel Function. (Pubmed Central) - Feb 17, 2021
Collectively, these novel findings demonstrate that chronic cART induces hyperexcitability of mPFC pyramidal neurons by abnormally promoting VGCC overactivation/overexpression of VGCCs (including, but may not limited to, LVA-Ca1.3 L-channels), which could complicate HIV-induced neurotoxicity, and ultimately may contribute to HIV-associated neurocognitive disorders (HAND) in PLWH. Determining additional target(s) of cART in mPFC pyramidal neurons may help to improve the therapeutic strategies by minimizing the side effects of cART for treating HIV/AIDS.
- |||||||||| Triumeq (dolutegravir/abacavir/lamivudine) / ViiV Healthcare, Vemlidy (tenofovir alafenamide) / Gilead
Biomarker, Clinical, Journal: Adenosine Deaminase as a Biomarker of Tenofovir Mediated Inflammation in Naïve HIV Patients. (Pubmed Central) - Feb 11, 2021
Plasma GM-CSF levels decreased after 12 months of treatment in the TDF group, with a concomitant decrease in blood monocyte count, and a negative correlation with ADA values was found. In conclusion, ADA levels may be modulated by antiretroviral therapy in HIV patients, possibly affecting inflammatory status.
- |||||||||| Triumeq (dolutegravir/abacavir/lamivudine) / ViiV Healthcare
Trial completion date, Trial primary completion date: Dolutegravir Study in HIV-1 Participants Completing IMPAACT Studies P1093 and P2019 (clinicaltrials.gov) - Dec 22, 2020
P3, N=300, Recruiting,
Further prospective research with a larger sample size must be conducted to evaluate the long-term effects of this therapeutic combination. Trial completion date: Dec 2023 --> Sep 2024 | Trial primary completion date: Dec 2023 --> Sep 2024
- |||||||||| bictegravir (GS-9883) / Gilead
PK/PD data, Journal: Pharmacokinetics of Co-encapsulated Antiretrovirals with Ingestible Sensors. (Pubmed Central) - Dec 18, 2020
To assess the safety and impact, if any, coencapsulation might have on ARV concentrations, we evaluated the pharmacokinetics of ARVs coencapsulated with an ingestible sensor for eight commonly used fixed-dose combination ARVs: emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF); FTC/tenofovir alafenamide (TAF); efavirenz (EFV)/FTC/TDF; abacavir (ABC)/lamivudine (3TC); dolutegravir (DTG)/ABC/3TC; rilpivirine (RPV)/TAF/FTC; elvitegravir (EVG)/cobicistat (COBI)/FTC/TAF; and bictegravir (BIC)/FTC/TAF...In a subsequent evaluation of FTC/TDF and BIC/FTC/TAF using a crossover design, the geometric mean ratio (GMR) between the coencapsulated and the unencapsulated formulations for FTC/TDF were the following: FTC, 84.6% (90% confidence interval [CI] 66.6-107.4) for AUC and 77.5% (60.1-99.9) for Cmax...The observed deviation in FTC/TDF (Truvada) may be due to participant characteristics, fasted/fed conditions, and/or random variation and may warrant further investigations with a larger sample size. These findings provide assurance for use of co-encapsulated ARVs for future HIV treatment-adherence research.
- |||||||||| Tivicay (dolutegravir) / ViiV Healthcare
Trial completion date, Trial primary completion date: Dolutegravir in Reservoirs (clinicaltrials.gov) - Nov 20, 2020
P=N/A, N=40, Suspended,
These findings provide assurance for use of co-encapsulated ARVs for future HIV treatment-adherence research. Trial completion date: Oct 2020 --> May 2021 | Trial primary completion date: Oct 2020 --> May 2021
- |||||||||| Triumeq (dolutegravir/abacavir/lamivudine) / ViiV Healthcare, Complera (emtricitabine/rilpivirine/tenofovir) / Gilead, J&J
Clinical, Observational data, Journal, HEOR: De-simplifying single-tablet antiretroviral treatments for cost savings in France: From the patient perspectives to a 6-month follow-up on generics. (Pubmed Central) - Nov 18, 2020
Fifty-one patients accepted to replace their single-tablet regimens and six months later, the majority was satisfied; only four returned to single-tablet regimens because of suspected side effects. Half of the people living with HIV/AIDS in our cohort accepted to switch from brand single-tablet regimens to a two-tablet regimen containing generic drugs within a process that emphasizes health expenditure savings.
- |||||||||| Triumeq (dolutegravir/abacavir/lamivudine) / ViiV Healthcare, VentaProst (epoprostenol inhalation) / Aerogen Pharma
[VIRTUAL] SCLEROTHERAPY OR SCLERODISTRESS? ARDS CAUSED BY SCLEROSING AGENTS USED FOR ROUTINE ARTERO-VENOUS MALFORMATION (AVM) EMBOLIZATION () - Oct 12, 2020 - Abstract #CHEST2020CHEST_1581;
His past medical history was significant for HIV (Last CD4 of 278 on Triumeq), ESRD previously on hemodialysis now status post a renal transplant, hypertension...Given this severity, he was started on lung-protective strategy, paralyzed, placed prone, and given inhaled epoprostenol... Further studies are needed to determine the extent and prevalence of major complications involved with routinely used sclerosing agents, risk factors contributing to these if any, so as to enable patients and providers to make an informed decision.
- |||||||||| Triumeq (dolutegravir/abacavir/lamivudine) / ViiV Healthcare
Journal: HIV-1 Tat and opioids act independently to limit antiretroviral brain concentrations and reduce blood-brain barrier integrity. (Pubmed Central) - Oct 2, 2020
To evaluate effects on antiretroviral brain penetration, Tat+ and Tat- mice received three antiretroviral drugs (dolutegravir, abacavir, and lamivudine) with or without concurrent morphine exposure...Collectively, our investigations indicate that Tat and morphine differentially alter BBB integrity. Morphine decreased brain concentrations of specific antiretroviral drugs, perhaps via increased expression of the drug efflux transporter, P-glycoprotein.
- |||||||||| Triumeq (dolutegravir/abacavir/lamivudine) / ViiV Healthcare, Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead, Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
[VIRTUAL] Persistence of antiretroviral therapy regimens among veterans with HIV newly initiating treatment in the US () - Sep 21, 2020 - Abstract #HIVGlasgow2020HIV-Glasgow_188;
Among US veterans with HIV, STR initiators were significantly less likely to discontinue first‐line therapy compared to MTR initiators. Veterans who initiated a BIC/FTC/TAF regimen had a lower risk of discontinuation compared to MTRs and other STRs included in the study.
- |||||||||| Triumeq (dolutegravir/abacavir/lamivudine) / ViiV Healthcare, Rekambys (rilpivirine LA) / J&J
[VIRTUAL] Patient-Reported Outcomes on Long-Acting Cabotegravir + Rilpivirine as Maintenance Therapy: FLAIR 96-Week Results () - Aug 14, 2020 - Abstract #IDWeek2020IDWEEK_1810;
At Week 96, FLAIR participants receiving LA therapy reported greater improvement in treatment satisfaction compared with participants continuing on daily oral medication as well as overall good acceptability of injections with improvement over time. Overall, these results support monthly CAB + RPV LA as an alternative to daily oral regimens for adults with HIV-1.
- |||||||||| Triumeq (dolutegravir/abacavir/lamivudine) / ViiV Healthcare, Vemlidy (tenofovir alafenamide) / Gilead
[VIRTUAL] Long-term Follow-up After a Switch to Bictegravir, Emtracitabine, Tenofovir Alafenamide from Dolutegravir, Abacavir, Lamivudine () - Aug 14, 2020 - Abstract #IDWeek2020IDWEEK_1676;
Background: Bictegravir, emtricitabine and tenofovir alafenamide (B/F/TAF) is a guidelines-recommended single-tablet regimen (STR) for people living with HIV-1 (PLWH). Extended follow-up to the study of switching to B/F/TAF from DTG/ABC/3TC, demonstrates continued high rates of virologic suppression with no resistance and excellent safety and tolerability of B/F/TAF through a maximum of 168 weeks for treatment of PLWH.
- |||||||||| Triumeq (dolutegravir/abacavir/lamivudine) / ViiV Healthcare
Enrollment closed, Enrollment change: ING200336, Pharmacokinetic and Safety Study in Pregnant Women With Human Immuno Virus Infection (clinicaltrials.gov) - Aug 9, 2020
P3, N=4, Active, not recruiting,
Extended follow-up to the study of switching to B/F/TAF from DTG/ABC/3TC, demonstrates continued high rates of virologic suppression with no resistance and excellent safety and tolerability of B/F/TAF through a maximum of 168 weeks for treatment of PLWH. Suspended --> Active, not recruiting | N=25 --> 4
- |||||||||| Triumeq (dolutegravir/abacavir/lamivudine) / ViiV Healthcare, lamivudine / Generic mfg., Tivicay (dolutegravir) / ViiV Healthcare
Biomarker, Clinical, Journal: Safety and tolerability of Triumeq in amyotrophic lateral sclerosis: the Lighthouse trial. (Pubmed Central) - Jul 22, 2020
P2a
Funding: Funding was provided by the FightMND Foundation; MND Research Institute of Australia; MND Association, United Kingdom, and GSK. ViiV Healthcare provided the Triumeq.
- |||||||||| Lacromid (bezafibrate) / Remedica
[VIRTUAL] PRIMARY BILIARY CHOLANGITIS WITH FEATURES OF AUTOIMMUNE HEPATITIS IN AN PATIENT WITH HIV INFECTION (Poster Exhibition) - Jul 19, 2020 - Abstract #UEGW2020UEGW_5639;
Clinical Case Summary: We present a 59 year-old man with known HIV infection since 2013, treated with abacavir, dolutegravir and lamivudine since then...Due to incomplete response to UDCA at 12 months (ALP 541 to 261 U/L) and since data concerning obeticholic acid with concomitant antiretroviral therapy were lacking, bezafibrate was added...It is believed that these autoimmunity phenomena occur in the context of inflammatory immune reconstitution induced by antiretroviral therapy. Therefore, in an era of generalization of this therapy, it is important to remain alert to this entity and its diagnostic and therapeutic challenges.
- |||||||||| Triumeq (dolutegravir/abacavir/lamivudine) / ViiV Healthcare
[VIRTUAL] A CASE OF INFECTIOUS ULCER OF THE ANUS WITH PSEUDOTUMORAL PRESENTATION (Poster Exhibition) - Jul 19, 2020 - Abstract #UEGW2020UEGW_5613;
Clinical Case Summary: A 51-year-old caucasian patient followed for HIV-1 infection, on dolutegravir, abacavir and lamivudine, with good virologic and immunologic response, reported a 1-month history of proctalgia, constipation and tenesmus...Differential diagnosis between these bacteria is difficult. There are no guidelines for IS treatment.
- |||||||||| Lacromid (bezafibrate) / Remedica
[VIRTUAL] PRIMARY BILIARY CHOLANGITIS WITH FEATURES OF AUTOIMMUNE HEPATITIS IN AN PATIENT WITH HIV INFECTION (Poster Exhibition) - Jul 19, 2020 - Abstract #UEGW2020UEGW_3663;
Clinical Case Summary: We present a 59 year-old man with known HIV infection since 2013, treated with abacavir, dolutegravir and lamivudine since then...Due to incomplete response to UDCA at 12 months (ALP 541 to 261 U/L) and since data concerning obeticholic acid with concomitant antiretroviral therapy were lacking, bezafibrate was added...It is believed that these autoimmunity phenomena occur in the context of inflammatory immune reconstitution induced by antiretroviral therapy. Therefore, in an era of generalization of this therapy, it is important to remain alert to this entity and its diagnostic and therapeutic challenges.
- |||||||||| Triumeq (dolutegravir/abacavir/lamivudine) / ViiV Healthcare
[VIRTUAL] A CASE OF INFECTIOUS ULCER OF THE ANUS WITH PSEUDOTUMORAL PRESENTATION (Poster Exhibition) - Jul 19, 2020 - Abstract #UEGW2020UEGW_3637;
Clinical Case Summary: A 51-year-old caucasian patient followed for HIV-1 infection, on dolutegravir, abacavir and lamivudine, with good virologic and immunologic response, reported a 1-month history of proctalgia, constipation and tenesmus...Differential diagnosis between these bacteria is difficult. There are no guidelines for IS treatment.
|
